<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5D4DA65E-A1B5-438A-A573-4AE1184ABA82"><gtr:id>5D4DA65E-A1B5-438A-A573-4AE1184ABA82</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Owen</gtr:otherNames><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/34A43238-220E-4ED1-8F56-ABF0DE9A8B14"><gtr:id>34A43238-220E-4ED1-8F56-ABF0DE9A8B14</gtr:id><gtr:firstName>Saba</gtr:firstName><gtr:surname>Alzabin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B51C320-78B1-4E3E-9040-66B1C175E97F"><gtr:id>7B51C320-78B1-4E3E-9040-66B1C175E97F</gtr:id><gtr:firstName>Sonya</gtr:firstName><gtr:surname>Abraham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D1BB1B6-A7EC-4CE0-942B-734C4A958A34"><gtr:id>0D1BB1B6-A7EC-4CE0-942B-734C4A958A34</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802513"><gtr:id>2F81B811-7596-4D6D-B13D-34F005B64B6D</gtr:id><gtr:title>A rational approach to the use of combination biologic therapy in rheumatoid arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802513</gtr:grantReference><gtr:abstractText>TNF antagonists are a new class of drugs that are used to treat rheumatoid arthritis and other autoimmune diseases. These drugs act by blocking the activity of a cytokine, known as TNF, that plays an important role in the disease process. Using a mouse model of rheumatoid arthritis, we have recently discovered that one of the unexpected consequences of TNF blockade is the increased production of another cytokine, IL-17, that also contributes to the disease process. Hence, the beneficial effects of anti-TNF therapy are offset by the deleterious effects of increased IL-17 production. On this basis we would predict that a combination of a TNF antagonist and an IL-17 antagonist would have an enhanced therapeutic effect and we have obtained preliminary evidence using a mouse model of arthritis to suggest that this is the case. In this proposal we will first establish that TNF antagonists increase IL-17 levels in patients with rheumatoid arthritis and other autoimmune diseases. Next, we will validate the concept of combination therapy using a TNF antagonist and an IL-17 antagonist in mice. This will provide the scientific rationale for conducting clinical trials of combination therapy in rheumatoid arthritis. Finally, we will seek to identify industrial partners interested in testing the concept of combination therapy in patients. This study will help to establish a novel approach to treatment that will have improved long-term efficacy over existing therapies.</gtr:abstractText><gtr:technicalSummary>TNF antagonists represent a major breakthrough in the treatment of a number of autoimmune and inflammatory diseases but there are serious obstacles to their more general use, including high cost and lack of durable therapeutic effect.
Using a mouse model of rheumatoid arthritis, we have recently discovered that one of the unexpected consequences of TNF blockade is the increased expression of IL-17, a potent pro-inflammatory cytokine. Thus, the beneficial effects of anti-TNF therapy are offset by the deleterious effects of increased IL-17 production. In addition, we have preliminary evidence in mice that anti-TNF and anti-IL-17 act synergistically to suppress arthritis and induce disease remission. In this proposal we will first establish that TNF blockade upregulates the IL-17 pathway in patients with rheumatoid arthritis and other autoimmune diseases. Next, we will confirm the ability of anti-TNF and anti-IL-17 to act synergistically in mice and establish the optimal form of combination therapy for use in human therapy. This will provide the scientific rationale for conducting clinical trials of combination biologic therapy in rheumatoid arthritis. The potential benefit of this study will be to establish a novel therapeutic approach which has improved long-term efficacy over existing therapies and which will increase the numbers of patients that can be treated effectively by TNF antagonists.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>489064</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Merck</gtr:description><gtr:id>C612B919-8E44-455E-A759-5572A54E8F05</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>UyNpSzmAozU-1</gtr:outcomeId><gtr:partnerContribution>Financial, inellectual and access to data.</gtr:partnerContribution><gtr:piContribution>This is a collaborative project in which our team are carrying out translational research. The project may lead to new treatments for rheumatoid arthritis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Barts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7B7FD789-448A-4D00-AA77-46269C812E95</gtr:id><gtr:impact>6th Gene Therapy of Arthritis and Related Disorders, London: &amp;quot;Anti-TNF and IL-17 in arthritis&amp;quot;

The presentation generated considerble interest.</gtr:impact><gtr:outcomeId>Zqk1PnRXpTn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Copenhagen</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDA864DF-603A-4E9E-B38E-B586F8406538</gtr:id><gtr:impact>More than 100 scientists and clinicians attended the presentation. World Congress of Basic Clinical Pharmacology, Copenhagen: &amp;quot;TNF-alpha antagonists - translating molecular insights in autoimmunity into effective therapy&amp;quot;

A webcast was made descibing our research.</gtr:impact><gtr:outcomeId>MTvXuFL4oxh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DA3B8340-9CD1-4F62-B9E7-8AE44AD68B64</gtr:id><gtr:impact>Members of the ARUK User's group (comprising patients and Healthcare professionals) attended a presentation on our work.

The group reported that they found the presentation highly informative.</gtr:impact><gtr:outcomeId>CifoAo6oeFV</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation Liverpool</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E6FBD1A0-EC3C-48C6-958E-BAB5DD0E40D2</gtr:id><gtr:impact>A presentation was given entitled 'TNFR inhibition for systemic inflammatory diseases' at a symposium focussed on drug discovery for pancreatic and GI disease. This formed a key part of the sessions on drug discovery for pancreatitis.

The meeting served as a stimulus for future collaborations.</gtr:impact><gtr:outcomeId>HEDYCg6HXxm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>92173</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F38982D1-6F74-4A73-8656-8F1D810F4C64</gtr:id><gtr:outcomeId>XG7Zgk89ZjP</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The discovery describes the synergistic effect of anti-TNF antibody therapy and anti-IL-23 antibody therapy.</gtr:description><gtr:grantRef>G0802513</gtr:grantRef><gtr:id>BE90C900-1EDC-4D04-992A-95CDC47EA07E</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>QQVTHtmNv1N</gtr:outcomeId><gtr:patentId>WO2011070339</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method of treating disease</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D7A0E0FE-BE5A-4694-B6B9-CDC9C4BFF5BE</gtr:id><gtr:title>Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b895fc54ee1d2bcc1c5ec0440cb2fa92"><gtr:id>b895fc54ee1d2bcc1c5ec0440cb2fa92</gtr:id><gtr:otherNames>Hull DN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>588b5d26d57359.68862941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16418402-7B1E-44AB-9986-70A341D78CF4</gtr:id><gtr:title>Incomplete response of inflammatory arthritis to TNFa blockade is associated with the Th17 pathway.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95b6933923a6160809f3cf48f6970fd9"><gtr:id>95b6933923a6160809f3cf48f6970fd9</gtr:id><gtr:otherNames>Alzabin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13551_21_22550316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7941C7A-DFEE-4F0D-867F-10BE26BA84C2</gtr:id><gtr:title>Effector T cells in rheumatoid arthritis: lessons from animal models.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95b6933923a6160809f3cf48f6970fd9"><gtr:id>95b6933923a6160809f3cf48f6970fd9</gtr:id><gtr:otherNames>Alzabin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>pm_13551_21_21515267</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802513</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>